AMENDMENT NO. 2 TO DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • November 19th, 2010 • Insulet Corp • Surgical & medical instruments & apparatus
This Amendment No. 2 (the “Amendment”) dated June 30, 2010 (“Amendment No. 2 Effective Date”) is entered into by and between Abbott Diabetes Care Inc., formerly known as TheraSense, Inc., (“ADC”) and Insulet Corporation (“Insulet”) to amend the Development and License Agreement entered into between TheraSense, Inc. (“Therasense”) and Insulet, effective as of January 23, 2002 and as amended on March 3, 2008 (together with this Amendment No. 2 hereinafter referred to collectively as the “Agreement”). Capitalized terms used herein but not otherwise defined shall have the meanings ascribed to them in the Agreement.
